Shares of iBio, Inc. (NYSEMKT:IBIO – Get Free Report) dropped 2.9% on Thursday . The company traded as low as $4.39 and last traded at $4.39. Approximately 321,644 shares were traded during trading, an increase of 184% from the average daily volume of 113,212 shares. The stock had previously closed at $4.52.
iBio Stock Performance
The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04. The business’s fifty day simple moving average is $3.89 and its two-hundred day simple moving average is $2.93.
iBio Company Profile
iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Featured Articles
- Five stocks we like better than iBio
- What is the Euro STOXX 50 Index?
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Are Penny Stocks a Good Fit for Your Portfolio?
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
